Non-opioid CIPN Targeted non-opioid topical candidate ATX01 for chemotherapy-induced peripheral neuropathy presents a potential narrative for partnerships with oncology clinics, pain management specialists, and hospital networks treating CIPN, offering an alternative therapy with Fast-Track designation.

Phase II momentum International Phase II trial results due early 2025 and plans to accelerate to Phase III suggest timing for investor and partner outreach, leveraging upcoming data to validate clinical benefit and disease area expansion with pharma or biotech co-development discussions.

Strategic funding Recent Series B funding and a broad investor base, including healthtech and life sciences funds, indicate credibility and potential for co-investment opportunities, licensing discussions, or collaboration with strategic pharma partners seeking early-stage CNS/pain franchises.

ESG endorsement France Biotech ESG HealthTech Trophy recognition signals alignment with sustainability and responsible innovation, which can be leveraged to engage ESG-conscious investors, grant programs, and government or NGO partnerships interested in ethical biotech development.

Clinical leadership Seasoned leadership with track record in bringing products to market, plus an international investor board, can be highlighted in outbound outreach to potential partners, licensors, or contract research organizations seeking experienced collaborators in oncology supportive care and pain therapeutics.